Legal & General Group Plc Buys Shares of 30,198 Oruka Therapeutics, Inc. $ORKA

Legal & General Group Plc bought a new stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 30,198 shares of the company’s stock, valued at approximately $2,874,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in ORKA. BNP Paribas Financial Markets raised its position in Oruka Therapeutics by 464.0% during the second quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock valued at $31,000 after purchasing an additional 2,306 shares in the last quarter. Royal Bank of Canada boosted its holdings in shares of Oruka Therapeutics by 47.2% in the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock valued at $34,000 after purchasing an additional 365 shares in the last quarter. Los Angeles Capital Management LLC bought a new position in shares of Oruka Therapeutics in the 4th quarter valued at $37,000. PNC Financial Services Group Inc. bought a new position in shares of Oruka Therapeutics in the 3rd quarter valued at $39,000. Finally, Russell Investments Group Ltd. acquired a new position in shares of Oruka Therapeutics during the 3rd quarter worth $43,000. Institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Stock Up 1.7%

NASDAQ ORKA opened at $92.51 on Friday. Oruka Therapeutics, Inc. has a twelve month low of $14.66 and a twelve month high of $115.51. The company has a market cap of $6.13 billion, a price-to-earnings ratio of -45.57 and a beta of -0.34. The business’s fifty day moving average is $95.24 and its 200 day moving average is $69.58.

Oruka Therapeutics (NASDAQ:ORKA) last issued its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). On average, research analysts anticipate that Oruka Therapeutics, Inc. will post -2.42 earnings per share for the current fiscal year.

Insider Transactions at Oruka Therapeutics

In related news, insider Joana Goncalves sold 7,000 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $111.84, for a total value of $782,880.00. Following the completion of the transaction, the insider owned 32,718 shares in the company, valued at $3,659,181.12. This trade represents a 17.62% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Carl Dambkowski sold 12,583 shares of the firm’s stock in a transaction that occurred on Friday, June 12th. The shares were sold at an average price of $70.11, for a total transaction of $882,194.13. Following the completion of the transaction, the director owned 38,743 shares of the company’s stock, valued at approximately $2,716,271.73. This trade represents a 24.52% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 158,116 shares of company stock valued at $13,523,783. 23.49% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Piper Sandler restated an “overweight” rating and set a $180.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, June 2nd. Wall Street Zen cut Oruka Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, August 16th. Guggenheim reissued a “buy” rating and set a $200.00 target price on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. BTIG Research reissued a “buy” rating and issued a $151.00 target price on shares of Oruka Therapeutics in a report on Tuesday, August 11th. Finally, Weiss Ratings upgraded shares of Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 15th. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $133.00.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.